TMCO1对宫颈癌细胞增殖和迁移能力的影响

doi:10.19401/j.cnki.1007-3639.2024.06.005

摘要/Abstract

摘要：

背景与目的：跨膜和卷曲螺旋结构域1（transmembrane and coiled-coil domains 1，TMCO1）是新近发现的一种内质网钙离子通道蛋白，已被发现与多种肿瘤的进展相关，但其在宫颈癌中的作用尚未明确。本研究旨在探讨TMCO1对宫颈癌HeLa细胞增殖和迁移能力的影响。方法：通过质粒转染宫颈癌HeLa细胞，获得稳定过表达TMCO1的细胞株和稳定敲减TMCO1的细胞株。采用细胞计数试剂盒-8（cell counting kit-8，CCK-8）实验、克隆形成实验和EdU标记实验检测细胞增殖能力，采用transwell实验检测细胞迁移能力，并将稳定过表达TMCO1细胞与对照细胞进行蛋白质组学分析。结果：CCK-8实验和克隆形成实验显示，宫颈癌HeLa细胞过表达TMCO1后，增殖能力显著增加（P<0.05）；EdU标记实验显示，宫颈癌HeLa细胞过表达TMCO1后，进行活跃DNA合成的细胞数量明显增多（P<0.01）。宫颈癌HeLa细胞敲减TMCO1后，细胞周期抑制蛋白p27表达增加，组蛋白H3的磷酸化减弱；克隆形成实验显示，敲减TMCO1显著抑制宫颈癌HeLa细胞的增殖（P<0.001）；EdU标记实验显示，宫颈癌HeLa细胞敲减TMCO1后，进行活跃DNA合成的细胞数量明显减少（P <0.05）。Transwell实验显示，宫颈癌HeLa细胞过表达TMCO1后，迁移能力显著增加（P<0.001）；敲减TMCO1显著抑制宫颈癌HeLa细胞的迁移（P<0.001）。稳定过表达TMCO1细胞中与细胞外基质-黏附及磷脂酰肌醇3-激酶（phosphoinositide3-kinase，PI3K）/蛋白激酶B（protein kinase B，AKT）信号转导通路显著激活，而核糖体相关等通路受到抑制。结论：TMCO1过表达显著促进宫颈癌HeLa细胞的增殖和迁移，敲减TMCO1显著抑制宫颈癌HeLa细胞的增殖和迁移，TMCO1可能通过调节细胞的黏附及信号转导影响HeLa细胞的增殖和迁移。

关键词: 宫颈癌, TMCO1, 增殖, 迁移

Abstract:

Background and purpose: Transmembrane and coiled-coil domains 1 (TMCO1) is a recently discovered endoplasmic reticulum calcium channel protein that has been found to be associated with the progression of various tumors, however, its role in cervical cancer has not yet been clarified. This study aimed to investigate the effects of TMCO1 on the proliferation and migration of cervical cancer HeLa cells. Methods: By transfecting cervical cancer HeLa cells with plasmids, cells with stable overexpression of TMCO1 and cells with stable knockdown of TMCO1 were obtained. Cell counting kit-8 (CCK-8) assay, clone formation assay and EdU labeling assay were used to detect cell proliferation ability, transwell assay was used to detect cell migration ability, and proteomic analysis was performed on the cells that stably overexpressed TMCO1 and control cells. Results: The CCK-8 experiment and clone formation experiment showed that overexpression of TMCO1 in cervical cancer HeLa cells significantly increased their proliferation ability (P<0.05). EdU labeling experiments showed that overexpression of TMCO1 in cervical cancer HeLa cells significantly increased the number of cells undergoing active DNA synthesis (P<0.01). After knocking down TMCO1 in cervical cancer HeLa cells, the expression of cell cycle inhibitory protein p27 increased, and the phosphorylation of histone H3 decreased. Clonogenesis experiments showed that knocking down TMCO1 significantly inhibited the proliferation of cervical cancer HeLa cells (P<0.001). EdU labeling experiments showed that after knocking down TMCO1 in cervical cancer HeLa cells, the number of cells undergoing active DNA synthesis was significantly reduced (P<0.05). Transwell experiment showed that overexpression of TMCO1 in cervical cancer HeLa cells significantly increased their migration ability (P<0.001), while knocking down TMCO1 significantly inhibited the migration of cervical cancer HeLa cells (P<0.001). The pathways related to extracellular matrix adhesion and PI3K-AKT signaling were significantly upregulated in the cells with stable overexpression of TMCO1, while ribosome related pathways were downregulated in proteomic analysis. Conclusion: Overexpression of TMCO1 significantly promotes the proliferation and migration of cervical cancer cells, while knockdown of TMCO1 significantly inhibits the proliferation and migration of cervical cancer HeLa cells. TMCO1 may affect the proliferation and migration of HeLa cells by regulating cell adhesion and signal transduction.

Key words: Cervical cancer, TMCO1, Proliferation, Migration

中图分类号:

R737.33

陈珣, 郑真霞, 阮雪茹. TMCO1对宫颈癌细胞增殖和迁移能力的影响[J]. 中国癌症杂志, 2024, 34(6): 571-580.

CHEN Xun, ZHENG Zhenxia, RUAN Xueru. Effects of TMCO1 on proliferation and migration of cervical cancer cells[J]. China Oncology, 2024, 34(6): 571-580.

图/表 5

参考文献 23

[1]	JEMAL A, SIEGEL R, XU J Q, et al. Cancer statistics. Ca cancer J clin[J]. CA A Cancer J Clin, 2010, 60(5): 277-300.
[2]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30.
[3]	CAO W, CHEN H D, YU Y W, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J, 2021, 134(7): 783-791.
[4]	GROENENDYK J, MICHALAK M. Interplay between calcium and endoplasmic reticulum stress[J]. Cell Calcium, 2023, 113: 102753.
[5]	LI W, OUYANG Z, ZHANG Q, et al. SBF-1 exerts strong anticervical cancer effect through inducing endoplasmic reticulum stress-associated cell death via targeting sarco/endoplasmic reticulum Ca(2+)-ATPase 2[J]. Cell Death Dis, 2014, 5(12): e1581.
[6]	WANG Q C, ZHENG Q X, TAN H Y, et al. TMCO1 is an ER Ca(2+) load-activated Ca(2+) channel[J]. Cell, 2016, 165(6): 1454-1466.
[7]	ZHANG N N, TANG M, WEN M R, et al. Expression, purification and characterization of TMCO1 for structural studies[J]. Protein Expr Purif, 2021, 179: 105803.
[8]	SUN Z S, ZHANG H, WANG X, et al. TMCO1 is essential for ovarian follicle development by regulating ER Ca²⁺ store of granulosa cells[J]. Cell Death Differ, 2018, 25(9): 1686-1701.
[9]	LI J W, LIU C Z, LI Y H, et al. TMCO1-mediated Ca²⁺ leak underlies osteoblast functions via CaMKⅡ signaling[J]. Nat Commun, 2019, 10(1): 1589.
[10]	BATCHELOR-REGAN H, XIN B Z, ZHOU A M, et al. From disease description and gene discovery to functional cell pathway: a decade-long journey for TMCO1[J]. Front Genet, 2021, 12: 652400.
[11]	ZHENG S L, WANG X W, ZHAO D, et al. Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communications[J]. Trends Cell Biol, 2023, 33(4): 312-323.
[12]	YANG X, ZHUANG J, SONG W L, et al. Mitochondria-associated endoplasmic reticulum membrane: overview and inextricable link with cancer[J]. J Cell Mol Med, 2023, 27(7): 906-919. doi: 10.1111/jcmm.17696 pmid: 36852470
[13]	LI C F, WU W R, CHAN T C, et al. Transmembrane and coiled-coil domain 1 impairs the AKT signaling pathway in urinary bladder urothelial carcinoma: a characterization of a tumor suppressor[J]. Clin Cancer Res, 2017, 23(24): 7650-7663.
[14]	ZHENG S L, ZHAO D, HOU G X, et al. iASPP suppresses Gp78-mediated TMCO1 degradation to maintain Ca²⁺ homeostasis and control tumor growth and drug resistance[J]. Proc Natl Acad Sci U S A, 2022, 119(6): e2111380119.
[15]	GAO L, YE Z, LIU J H, et al. TMCO1 expression promotes cell proliferation and induces epithelial-mesenchymal transformation in human gliomas[J]. Med Oncol, 2022, 39(5): 90.
[16]	YANG C, WANG Y, BAI J Q, et al. Mechanism of transmembrane and coiled-coil domain 1 in the regulation of proliferation and migration of A549 cells[J]. Oncol Lett, 2020, 20(5): 159.
[17]	SUN G Y, GONG S, LAN S W, et al. TMCO1 regulates cell proliferation, metastasis and EMT signaling through CALR, promoting ovarian cancer progression and cisplatin resistance[J]. Cell Mol Biol, 2024, 70(1): 99-109.
[18]	殷苏威, 张裕民, 郭丽, 等. Irisin通过PI3K/AKT/Cyclin D1途径促进宫颈癌HeLa细胞增殖的机制研究[J]. 中国计划生育和妇产科, 2022, 14(5): 100-105.
	YIN S W, ZHANG Y M, GUO L, et al. The mechanism research of Irisin promoting the proliferation of cervical cancer HeLa cells through PI3K/AKT/Cyclin D1 pathway[J]. Chin J Fam Plan Gynecotokol, 2022, 14(5): 100-105.
[19]	CHEN L, LIU D M, YI X F, et al. The novel miR-1269b-regulated protein SVEP1 induces hepatocellular carcinoma proliferation and metastasis likely through the PI3K/Akt pathway[J]. Cell Death Dis, 2020, 11(5): 320.
[20]	DAI B L, YU R Z, FAN M Y, et al. HMQ-T-F2 suppresses migration of the human cervical cancer HeLa cells by reversing EMT via the PI3K/Akt signaling pathway[J]. Oncol Rep, 2019, 42(4): 1451-1458.
[21]	PELLETIER J, THOMAS G, VOLAREVIĆ S. Ribosome biogenesis in cancer: new players and therapeutic avenues[J]. Nat Rev Cancer, 2018, 18(1): 51-63. doi: 10.1038/nrc.2017.104 pmid: 29192214
[22]	PRAKASH V, CARSON B B, FEENSTRA J M, et al. Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease[J]. Nat Commun, 2019, 10(1): 2110. doi: 10.1038/s41467-019-10100-8 pmid: 31068593
[23]	KUDO M, ANAM M B, ISTIAQ A, et al. Ribosome incorporation induces EMT-like phenomenon with cell cycle arrest in human breast cancer cell[J]. Cells Tissues Organs, 2022, 211(2): 212-221.